Scantox Neuro GMBH
Grambach, Steiermark
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- SAM.gov registration date
- Physical address
- Parkring 12, 8074 Grambach, Austria
- Website
- scantox.com
- Founded
- 1977
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $21,788 |
Contract awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| QPS Austria GMBH | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Artery Therapeutics, Inc. | San Ramon, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gifford Bioscience LIMITED | England | 621511 Medical Laboratories |
| Neurano Bioscience LLC | Encinitas, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Research And Development | San Diego, CA | — |
About the company
Scantox Neuro GMBH is a for-profit corporate entity registered in SAM.gov, specializing in pharmaceutical research and laboratory services focused on neurological and Alzheimer's disease research. The organization appears to be based in Austria and provides specialized scientific services to federal agencies, with a particular emphasis on experimental drug validation and pharmacological research. Its core competencies include conducting advanced scientific studies involving reagent materials, drug tolerability assessments, and experimental validation of potential medical treatments.
The organization has received multiple federal contract awards from the National Institute on Aging (NIA), primarily focused on Alzheimer's disease research. These contracts, totaling approximately $1.37 million, involve sophisticated scientific work such as pharmacodynamic and tolerability studies of candidate Alzheimer's drugs using transgenic mouse models. The contracts have consistently been firm fixed-price purchase orders and delivery orders, with no specific small business set-aside designations. Scantox Neuro GMBH's work has been integral to ongoing NIA research initiatives like the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and PREVENT-AD studies, involving experimental validation of potential treatments, chiral separation/purification processes, and testing of compounds like hydroxychloroquine sulfate and poly(L-lysine succinylated)-hydroxychloroquine.
Scantox Neuro GMBH has been awarded an Indefinite Delivery Contract (IDC) valued at $2,326,159.08 through the National Institute on Aging, with a performance period extending to May 31, 2025. This single-award IDC supports experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The IDC allows for multiple delivery orders, with three confirmed task orders already issued totaling approximately $1.7 million. The contract enables the company to conduct advanced scientific research involving testing candidate treatments in transgenic Alzheimer's mouse models, with the broader goal of investigating potential new treatment options through drug repurposing strategies.
Quick answers
Is Scantox Neuro GMBH registered in SAM.gov?
Yes. Scantox Neuro GMBH's SAM.gov registration is active through November 14, 2026.
What is Scantox Neuro GMBH's CAGE code?
Scantox Neuro GMBH's CAGE code is 3613N, and its Unique Entity ID (UEI) is ED41XCPBEPU1.
How much has Scantox Neuro GMBH received in federal contracts?
Federal contracts obligated $21,788 to Scantox Neuro GMBH in fiscal year 2025.
What is Scantox Neuro GMBH's most recent federal award?
Scantox Neuro GMBH's most recent federal contract award is Reagent materials - hydroxy chloroquine sulphate and chiral separation/purification (75N95D25P00029), from National Institute on Aging (NIH), on December 23, 2024.
On GovTribe
See Scantox Neuro GMBH's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors